Sapheon is focused on regulatory approval in Europe and Asia Pacific. Sapheon plans to expand our European and Asian marketing, distribution, training and sales activities while we simultaneously engage in clinical and regulatory activities in the United States. We are confident Sapheon's paradigm shifting technology will be well received by patients, physicians and third party providers and has the potential of becoming the gold standard for treating venous reflux disease.